MX2007008065A - Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos. - Google Patents

Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.

Info

Publication number
MX2007008065A
MX2007008065A MX2007008065A MX2007008065A MX2007008065A MX 2007008065 A MX2007008065 A MX 2007008065A MX 2007008065 A MX2007008065 A MX 2007008065A MX 2007008065 A MX2007008065 A MX 2007008065A MX 2007008065 A MX2007008065 A MX 2007008065A
Authority
MX
Mexico
Prior art keywords
compositions
self
gene expression
methods
modulating gene
Prior art date
Application number
MX2007008065A
Other languages
English (en)
Inventor
Todd M Hauser
Aaron Loomis
Original Assignee
Todd M Hauser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Todd M Hauser filed Critical Todd M Hauser
Publication of MX2007008065A publication Critical patent/MX2007008065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invencion se refiere a moleculas novedosas de acido nucleico que incluyen una region complementaria a un gen objetivo y una o mas regiones autocomplementarias, y al uso de dichas moleculas de acido nucleico y a composiciones que comprenden las mismas para modular la expresion genetica y al tratamiento de una variedad de enfermedades e infecciones.
MX2007008065A 2004-12-30 2005-12-30 Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos. MX2007008065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64058404P 2004-12-30 2004-12-30
PCT/US2005/047610 WO2006074108A2 (en) 2004-12-30 2005-12-30 Compositions and methods for modulating gene expression using self-protected oligonucleotides

Publications (1)

Publication Number Publication Date
MX2007008065A true MX2007008065A (es) 2008-03-04

Family

ID=36648075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008065A MX2007008065A (es) 2004-12-30 2005-12-30 Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.

Country Status (7)

Country Link
US (1) US20090005332A1 (es)
EP (1) EP1838875A4 (es)
JP (1) JP2008526213A (es)
CN (1) CN101124339A (es)
BR (1) BRPI0519690A2 (es)
MX (1) MX2007008065A (es)
WO (1) WO2006074108A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110159586A1 (en) * 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
WO2010045384A2 (en) 2008-10-15 2010-04-22 Somagenics Inc. Short hairpin rnas for inhibition of gene expression
JP5875976B2 (ja) * 2009-06-01 2016-03-02 ヘイロー−バイオ アールエヌエーアイ セラピューティクス， インコーポレイテッド 多価ｒｎａ干渉のためのポリヌクレオチド、組成物およびそれらの使用方法
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2454371B1 (en) 2009-07-13 2021-01-20 Somagenics, Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
WO2011038160A2 (en) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
SG196779A1 (en) * 2010-07-08 2014-02-13 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
CN103052711B (zh) * 2010-08-03 2016-08-03 株式会社博纳克 具有含氮脂环式骨架的单链核酸分子
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
ES2707232T3 (es) 2011-12-16 2019-04-03 Univ Nat Corp Tokyo Medical & Dental Acido nucleico bicatenario quimérico
US9528111B2 (en) 2012-01-07 2016-12-27 Bonac Corporation Single-stranded nucleic acid molecule having amino acid backbone
EP2857513A4 (en) 2012-05-26 2016-05-25 Bonac Corp SINGLE STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING THE EXPRESSION OF A GENE HAVING AN ADMINISTRATION FUNCTION
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CN105899663B (zh) 2013-12-26 2019-07-26 学校法人东京医科大学 用于基因表达控制的人工模拟miRNA及其用途
CN112646812A (zh) 2013-12-27 2021-04-13 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
JP6471176B2 (ja) 2014-12-27 2019-02-13 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
EP3276003B1 (en) 2015-03-27 2022-07-20 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
CN108342386B (zh) * 2017-01-22 2022-04-15 广州市锐博生物科技有限公司 一种多聚寡核酸分子及其在多靶标干扰中的应用
JP2024530943A (ja) 2021-08-06 2024-08-27 アンスティテュ・レジオナル・デュ・カンセール・ドゥ・モンペリエ がんの処置のための方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU4770093A (en) * 1992-07-02 1994-01-31 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
WO1994029442A2 (en) * 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5856174A (en) * 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
AU729655B2 (en) * 1996-11-12 2001-02-08 Regents Of The University Of California, The Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US5874554A (en) * 1996-12-13 1999-02-23 Incyte Pharmaceuticals, Inc. Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1115859A2 (en) * 1998-09-21 2001-07-18 Ribozyme Pharmaceuticals, Inc. Hairpin hybridizer molecules for modulation of gene expression
EP1173561A2 (en) * 1999-01-29 2002-01-23 Avi Biopharma, Inc. Non-invasive method for detecting target rna
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
FR2790757B1 (fr) * 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020086356A1 (en) * 2000-03-30 2002-07-04 Whitehead Institute For Biomedical Research RNA sequence-specific mediators of RNA interference
PL218876B1 (pl) * 2000-12-01 2015-02-27 Europaisches Lab Für Molekularbiologie Embl Wyizolowana cząsteczka dwuniciowego RNA, sposób wytwarzania cząsteczki dwuniciowego RNA, zastosowanie cząsteczki dwuniciowego RNA do wytwarzania leku do modulowania działania genu związanego z patogenem, genu związanego z nowotworem, oraz genu związanego z chorobą autoimmunologiczną, sposób in vitro kierowania miejscowo specyficznymi interferencjami RNA w komórce, zastosowanie sposobu in vitro do ustalania działania genu w komórce oraz do modulowania działania genu w komórce, środek farmaceutyczny, komórka eukariotyczna transfekowana cząsteczką RNA lub cząsteczką DNA kodującą tę cząsteczkę RNA, oraz zastosowanie komórki eukariotycznej w procedurach analitycznych oraz w procedurach preparatywnych
ES2358187T3 (es) * 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
JP2005508306A (ja) * 2001-07-23 2005-03-31 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 哺乳類における遺伝子発現のＲＮＡｉによる阻害に関する方法および組成物
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20060035344A1 (en) * 2002-10-18 2006-02-16 Pachuk Catherine J Double-stranded rna structures and constructs, and methods for generating and using the same
EP1604022A2 (en) * 2003-03-06 2005-12-14 Oligo Engine, Inc. Modulation of gene expression using dna-rna hybrids
GB0306575D0 (en) * 2003-03-21 2003-04-30 Inst Of Molecul & Cell Biology Modulators
US20050148531A1 (en) * 2003-05-15 2005-07-07 Todd Hauser Modulation of gene expression using DNA-DNA hybrids
US20070033062A1 (en) * 2005-04-28 2007-02-08 Oligoengine, Inc. Business methods, systems, and computer programs for designing customized biological assays and producing related catalogs and kits
EP2118319A4 (en) * 2007-02-12 2010-08-04 Univ Johns Hopkins PRECIOUS AND PROGNOSTIC DETECTION OF COLON CANCER

Also Published As

Publication number Publication date
JP2008526213A (ja) 2008-07-24
US20090005332A1 (en) 2009-01-01
EP1838875A2 (en) 2007-10-03
CN101124339A (zh) 2008-02-13
WO2006074108A3 (en) 2007-04-12
WO2006074108A2 (en) 2006-07-13
EP1838875A4 (en) 2010-08-25
BRPI0519690A2 (pt) 2009-03-03

Similar Documents

Publication Publication Date Title
MX2007008065A (es) Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
WO2009076321A3 (en) Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2004080377A3 (en) Kcnq channel modulating compounds and their pharmaceutical use
WO2005019418A3 (en) Modulation of diacylglycerol acyltransferase 2 expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2003008543A3 (en) Antisense modulation of bcl2-associated x protein expression
WO2004048534A3 (en) Modulation of cytokine-inducible kinase expression
WO2004055162A3 (en) Modulation of endothelial lipase expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2005042552A3 (en) Modulation of sglt2 expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2005086804A3 (en) Modulation of ace2 expression
WO2005021727A3 (en) Isoform-specific targeting of splice variants
WO2010017240A3 (en) Aurora kinase modulators and methods of use
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection
WO2005006958A8 (en) Modulation of ceacam1 expression
WO2004003201A3 (en) Antisense modulation of lrh1 expression
WO2004047750A3 (en) Modulation of notch2 expression
WO2004014299A3 (en) Antisense modulation of resistin expression